The evolution of the regulatory framework for antibacterial agents

Annals of the New York Academy of Sciences

Volumn 1323, Issue 1, 2014, Pages 11-21

  Rex, John H ^a,b   Goldberger, Mark ^c   Eisenstein, Barry I ^d   Harney, Carrie ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c ABBVIE INC   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Antibacterial drug development; Antibacterial resistance; Regulatory framework

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG USE; HUMAN; NONHUMAN; PHARMACODYNAMICS; PRESCRIPTION; REGULATORY MECHANISM; REIMBURSEMENT; ANTIBACTERIAL DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; REGULATORY FRAMEWORK; REVIEW; UNITED STATES;

ANTIBACTERIAL DRUG DEVELOPMENT; ANTIBACTERIAL RESISTANCE; REGULATORY FRAMEWORK;

ANTI-BACTERIAL AGENTS; MICROBIAL SENSITIVITY TESTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907958795     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12441     Document Type: Article

References (44)

1. Anonymous. 2013. Antibiotic resistance threats in the United States, 2013. US Dept HHS, Centers for Disease Control and Prevention. http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed April 13, 2014.
2. Anonymous. 2009. The bacterial challenge: time to reach. European CDC/European Medicines Agency Joint Technical Report. http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?ID=199&List=4f55ad51-4aed-4d32-b960-af70113dbb90. Accessed April 13, 2014.
3. Boucher, H.W., G.H. Talbot, D.K. Benjamin, Jr., et al. 2013. 10 x '20 progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56: 1685-1694.
4. Outterson, K., J.H. Powers, E. Seoane-Vazquez, et al. 2013. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J. Law Med. Ethics 41: 688-696.
5. Morel, C.M. & E. Mossialos . 2010. Stoking the antibiotic pipeline. BMJ 340: 1115-1118.
6. Spellberg, B., M. Blaser, R.J. Guidos, et al. 2011. Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52(Suppl 5): S397-428.
7. Projan, S.J. 2003. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6: 427-430.
8. Chastre, J., R. Wunderink, P. Prokocimer, et al. 2008. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 36: 1089-1096.
9. Brun-Buisson, C., J.P. Sollet, H. Schweich, et al. 1998. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin. Infect. Dis. 26: 346-354.
10. Lucasti, C., A. Jasovich, O. Umeh, et al. 2008. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin. Ther. 30: 868-883.
11. Naber, K.G., L. Llorens, K. Kaniga, et al. 2009. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob. Agents Chemother. 53: 3782-3792.
12. Wunderink, R.G., M.S. Niederman, M.H. Kollef, et al. 2012. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 54: 621-629.
13. Alemayehu, D., J. Quinn, J. Cook, et al. 2012. A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens. Clin. Infect. Dis. 55: 562-567.
14. Rex, J.H., B.I. Eisenstein, J. Alder, et al. 2013. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect. Dis. 13: 269-275.
15. Ambrose, P.G., S.M. Bhavnani, E.J. Ellis-Grosse & G.L. Drusano, 2010. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin. Infect. Dis. 51: S103-S110.
16. Ambrose, P.G. 2008. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design. Clin. Infect. Dis. 47: S225-S231.
17. Drusano, G.L. 2007. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin. Infect. Dis. 45: S89-S95.
18. Lee, J.Y., C.E. Garnett, J.V. Gobburu, et al. 2011. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin. Pharmacokinet. 50: 627-635.
19. Peck, C.C., D.B. Rubin, & L.B. Sheiner, 2003. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin. Pharmacol. Ther. 73: 481-490.
20. Shadish, W.R., R. Galindo, V.C. Wong, et al. 2011. A randomized experiment comparing random and cutoff-based assignment. Psychol. Methods 16: 179-191.
21. Gamalo, M.A., R.C. Tiwari & L.M. Lavange . 2014. Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products. Pharm Stat. 13: 25-40.
22. Viele, K., S. Berry, B. Neuenschwander, et al. 2014. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 13: 41-54.
23. Pucci, M.J. & K. Bush . 2013. Investigational antimicrobial agents of 2013. Clin. Microbiol. Rev. 26: 792-821.
24. Caliendo, A.M., D.N. Gilbert, C.C. Ginocchio, et al. 2013. Better tests, better care: improved diagnostics for infectious diseases. Clin. Infect. Dis. 57(Suppl 3): S139-S170.
25. Infectious Diseases Society of America. 2012. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin. Infect. Dis. 55: 1031-1046.
26. Anonymous. 2013. Guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. US Dept HHS, FDA, CDER, CBER. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed April 13, 2014.
27. Shlaes, D.M. & B. Spellberg . 2012. Overcoming the challenges to developing new antibiotics. Curr. Opin. Pharmacol. 12: 522-526.
28. Committee for Medicinal Products for Human Use (CHMP). 2013. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. European Medicines Agency, EMA/CHMP/351889/2013.
29. Talbot, G.H., J.H. Powers, T.R. Fleming, et al. 2012. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55: 1114-1121.
30. Powers, J.H. 2012. Editorial commentary: asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials. Clin. Infect. Dis. 54: 1710-1713.
31. Ambrose, P.G., J.P. Hammel, S.M. Bhavnani, et al. 2012. Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics. Antimicrob. Agents Chemother. 56: 1466-1470.
32. Dudley, M.N. & P.G. Ambrose . 2000. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol. 3: 515-521.
33. Anonymous. 2009. Guidance for industry: microbiological data for systemic antibacterial drug products-development, analysis, and presentation. US Dept HHS, FDA, CDER and CBER, September. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064980.htm.
34. Dudley, M.N., P.G. Ambrose & R.N. Jones . 2013. Commentary: revised susceptibility breakpoints: fear, loathing and good science. Pediatr. Infect. Dis. J. 32: 970-971.
35. Mouton, J.W., D.F. Brown, P. Apfalter, et al. 2012. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin. Microbiol. Infect. 18: E37-45.
36. Turnidge, J.D. 2011. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints. Clin. Infect. Dis. 52: 917-924.
37. Dudley, M.N., P.G. Ambrose, S.M. Bhavnani, et al. 2013. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin. Infect. Dis. 56: 1301-1309.
38. Rex, J.H., M.A. Pfaller, J.N. Galgiani, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24: 235-247.
39. Anonymous. 2000. 65 Fed. Reg. 81082, 81083. US Dept HHS, FDA.
40. Anonymous. 2009. Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices. US Dept HHS, FDA, CDER, CBER. http://www.fda.gov/regulatoryinformation/guidances/ucm125126.htm. Accessed April 13, 2014.
41. Hollis, A. & Z. Ahmed . 2013. Preserving antibiotics, rationally. N. Engl. J. Med. 369: 2474-2476.
42. Sharma, P. & A. Towse . 2010. New drugs to tackle antimicrobial resistance. Office of Health Economics, London. http://www.ohe.org/publications/article/new-drugs-to-tackle-antimicrobial-resistance-analysis-of-eu-policy-options-21.cfm. Accessed April 13, 2014.
43. Spellberg, B., P. Sharma & J.H. Rex . 2012. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat. Rev. Drug Discov. 11: 168.
44. Spellberg, B. & J.H. Rex . 2013. The value of single-pathogen antibacterial agents. Nat. Rev. Drug Discov. 12: 963.